Sandoz secures FDA approval for pegfilgrastim biosimilar Ziextenzo

This article was originally published here

Ziextenzo, like its reference drug pegfilgrastim, has been indicated to reduce the chances of infection caused by low white blood cell count with a fever – a condition

The post Sandoz secures FDA approval for pegfilgrastim biosimilar Ziextenzo appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply